TWI879855B - 融合蛋白在治療年齡相關性黃斑變性中的應用 - Google Patents

融合蛋白在治療年齡相關性黃斑變性中的應用 Download PDF

Info

Publication number
TWI879855B
TWI879855B TW109145708A TW109145708A TWI879855B TW I879855 B TWI879855 B TW I879855B TW 109145708 A TW109145708 A TW 109145708A TW 109145708 A TW109145708 A TW 109145708A TW I879855 B TWI879855 B TW I879855B
Authority
TW
Taiwan
Prior art keywords
eye
once
weeks
ibi302
group
Prior art date
Application number
TW109145708A
Other languages
English (en)
Chinese (zh)
Other versions
TW202128746A (zh
Inventor
盧淑傑
錢鐳
Original Assignee
大陸商信達生物製藥（蘇州）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商信達生物製藥（蘇州）有限公司 filed Critical 大陸商信達生物製藥（蘇州）有限公司
Publication of TW202128746A publication Critical patent/TW202128746A/zh
Application granted granted Critical
Publication of TWI879855B publication Critical patent/TWI879855B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW109145708A 2019-12-24 2020-12-23 融合蛋白在治療年齡相關性黃斑變性中的應用 TWI879855B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201911346311.2 2019-12-24
CN201911346311 2019-12-24
CN202011441025 2020-12-11
CN202011441025.7 2020-12-11

Publications (2)

Publication Number Publication Date
TW202128746A TW202128746A (zh) 2021-08-01
TWI879855B true TWI879855B (zh) 2025-04-11

Family

ID=76575187

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109145708A TWI879855B (zh) 2019-12-24 2020-12-23 融合蛋白在治療年齡相關性黃斑變性中的應用
TW113142581A TW202525865A (zh) 2019-12-24 2020-12-23 融合蛋白在治療年齡相關性黃斑變性中的應用

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113142581A TW202525865A (zh) 2019-12-24 2020-12-23 融合蛋白在治療年齡相關性黃斑變性中的應用

Country Status (8)

Country Link
US (1) US20230056821A1 (https=)
EP (1) EP4082559A4 (https=)
JP (2) JP2023509880A (https=)
CN (2) CN118750581A (https=)
AU (2) AU2020414152B2 (https=)
CA (1) CA3165887A1 (https=)
TW (2) TWI879855B (https=)
WO (1) WO2021129658A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082563A1 (en) * 2011-12-01 2013-06-06 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
CN104940926A (zh) * 2014-09-25 2015-09-30 信达生物制药(苏州)有限公司 重组融合蛋白制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105435222B (zh) * 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082563A1 (en) * 2011-12-01 2013-06-06 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
CN104940926A (zh) * 2014-09-25 2015-09-30 信达生物制药(苏州)有限公司 重组融合蛋白制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 馮宇梁等人 IBI302對實驗性脈絡膜新生血管的干預作用及機制研究 中華眼底病雜誌 第2期 2016年 第177-183頁;網路文獻 NCT03814291： A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration. Version 1, Date submitted: 2019-01-22 ，首次發佈2019-01-24 *
網路文獻 NCT03814291： A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration. Version 1, Date submitted: 2019-01-22 ，首次發佈2019-01-24

Also Published As

Publication number Publication date
CN118750581A (zh) 2024-10-11
EP4082559A4 (en) 2024-01-03
JP2024167222A (ja) 2024-12-03
AU2020414152B2 (en) 2025-02-13
EP4082559A1 (en) 2022-11-02
CA3165887A1 (en) 2021-07-01
CN114867489A (zh) 2022-08-05
AU2020414152A1 (en) 2022-08-04
TW202128746A (zh) 2021-08-01
TW202525865A (zh) 2025-07-01
AU2025203373A1 (en) 2025-05-29
WO2021129658A1 (zh) 2021-07-01
JP2023509880A (ja) 2023-03-10
US20230056821A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
US20250268983A1 (en) Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
TWI879855B (zh) 融合蛋白在治療年齡相關性黃斑變性中的應用
US20130190278A1 (en) Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases
US11478465B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
Kim et al. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion
US20120101033A1 (en) Retinitis pigmentosa treatment
Aşikgarip et al. Macular ganglion cell complex changes in eyes treated with aflibercept for neovascular age-related macular degeneration
Semeraro et al. Intravitreal infliximab for choroidal neovascularization in patients refractory to conventional treatments
WO2025036488A9 (en) Methods of treating age-related macular degeneration and diabetic macular edema
KR20260054713A (ko) 노인성 황반 변성 및 당뇨병성 황반 부종의 치료 방법
EP4640702A1 (en) Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases
Ulutas et al. Does intravitreal injection of aflibercept affect the corneal endothelium?
Hakan et al. Evaluation Of The Effectiveness Of Intravitreal Anti-VEGF Injection With Intravitreal Dexamethasone Implant In Patients With Treatment-Resistant Diabetic Macular Edema
Mautino et al. Side effects of drugs used in ocular treatment
Rodriguez 3 Chapter Pediatric Ocular Pharmacology
HK40125761A (en) Use of a vegf antagonist to treat angiogenic eye disorders
JP2025517038A (ja) 黄斑浮腫又は網膜静脈閉塞の治療における使用のための単量体アネキシンａ５
HK40094966A (en) Use of a vegf antagonist to treat diabetic retinopathy
EA051980B1 (ru) Расширенные схемы применения высоких доз антагониста vegf для лечения ангиогенных нарушений со стороны глаза
Bandello et al. New perspectives in the management of post-surgical macular edema
OPTHALMOLOGY A MULTIVARIATE ANALYSIS OF INTRA VITREAL INJECTION OF ANTI VEGF BEVACIZUMAB IN THE TREATMENT OF RETINAL AND CHOROIDAL NEOVASCULARISATION
Fernandez-Lloris Association for Research in Vision and Ophthalmology (ARVO)-2015 Annual Meeting. Denver, Colorado, USA-May 3-7, 2015
EA046420B1 (ru) Применение антагониста vegf для лечения ангиогенных глазных заболеваний
Al-Shamahi Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Seattle, Washington, USA-May 5-9, 2013
Ferrer et al. Ophthalmic therapeutics: new basic research and clinical studies